Seroprevalence of bactericidal antimeningococcal antibodies in Cantabria (Spain) 10 months after vaccination campaign;Seroprevalencia de anticuerpos bactericidas frente al meningococo c en Cantabria 10 meses despues de la campana de vacunacion

Revista Espanola de Salud Publica

Volumn 72, Issue 4, 1998, Pages 365-374

  De Aledo Linos, Álvaro González ^a,b   García Merino, Jesús ^a  

^a Gobierno de Cantabria ^*

^b Dir General de Sanidad y Consumo   (Spain)

Author keywords

Antibodies; Immune Response; Meningococcus C; Polysaccharide A + C meningococcic vaccine; Serum

Indexed keywords

ANTIBODY; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; CHILD; DRUG EFFICACY; HEALTH PROMOTION; HUMAN; MAJOR CLINICAL STUDY; NEISSERIA MENINGITIDIS; SEROPREVALENCE; SPAIN; VACCINATION;

EID: 7844241554     PISSN: 11355727     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1135-57271998000400008     Document Type: Article

References (19)

1. Gonzalez Arraez JI, Saiz Sanchez C, Cortina Birlanga S y Cortina Greus P. Vacunas frente al meningococo serogrupo C. Med Integral 1997; 30: 222-226.
2. Cortina S, Talamante S, Corella D y Giménez FJ. Situacíon actual de las vacunas antimeningocócicas. Med Integral 1997; 29: 84-87.
3. De Wals P, Dionne M, Douville-Fradet M, Boulianne N, Drapeau J and De Serres G. Impact of a mass immunization campaign against serogroup C meningococcus in the province of Quebec, Canada. WHO Bulletin 1996; 74: 407-411.
4. Riedo FX, Plicaytis BD and Broome CV. Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J 1995; 14 643-57.
5. Maslanka SE, Gheesling LL, Libutti DE, Donaldson K, Harakeh HS, Dykes JK et al. Standardization and Multilaboratory comparison of Neisseria Meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Labor Inmunol 1997; 4: 156-167.
6. Dean AC, Dean JA, Coulombier D et al. Epi Info Version 6: a word processing, database and statistics program for epidemiology on microcomputers. Georgia: Centers for Disease Control and Prevention: 1994.
7. Mitchell LA, Ochnio JJ, Glover C, Lee AY, Ho M and Bell A. Analysis of meningococcal serogroup C-specific antibody levels in British Columbia children and adolescents. J Infect Dis 1996; 173: 1009-13.
8. Peltola H, Safari A, Kayhty H, Karanko V, y André FE. Valoración de dos vacunas meningocócicas tetravalentes (ACYW135) en lactantes y niños pequeños. Estudio clínico comparando el efecto inmunógeno de los polisacáridos 0-acetil negativo y 0-acetil positivo del grupo C. Pediatrics (ed.esp.) 1985; 20: 54-58.
9. Ministerio de Sanidad Y Consumo, Instituto de Salud Carlos III, Agencia de Evaluación de las Tecnologías Sanitarias (AETS). Eficacia de la vacuna meningocócica de polisacárido capsular del grupo C. Madrid: AETS - Instituto de Salud Carlos III; 1997.
10. King WJ, Macdonald NE, Wells G, Huang J, Allen U, Chan F et al. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children. J Pediatr 1996; 128: 196-202.
11. Lepow ML, Beeler J, Randolph M, Samuelson JS and Hankins WA. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis 1986; 154: 1033-1036.
12. Gold R, Lepow ML, Goldschneider I, Draper TF, and Gotschlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children J Infect Dis 1979; 140: 690-97
13. Lepow ML, Goldschneider I, Gold R, Randolph M and Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977; 60: 673-680.
14. Gold R, Lepow ML, Goldschneider I, Draper TL and Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975; 56: 1536-1547.
15. Centers For Disease Control And Prevention. Control and prevention of meningococcal disease and Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks recommendations of the Advisory Committee on Inmunization Practices (ACIP). MMWR 1997; 46 (No. RR-5): 1-21.
16. Pearce MC, Sheridan JW, Jones DM, Lawrence GW, Murphy DM, Masutti B et al. Control of group C meningococcal disease in australian aboriginal children by mass rifampicin chemoprofilaxis and vaccination. The Lancet 1995; 346: 20-23.
17. rican Academy of Pediatrics. Meningococcal disease prevention and control strategies for practice-based physicians. Pediatrics 1996; 97. 404-411.
18. Leach A, Twumasi PA, Kumach S, Banya WS, Jaffar S, Forrest BD et al. Induction of immunologic memory in Gambian children by vaccinationin infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997; 175: 200-204.
19. Direccion Xeral de Saude Publica, Xunta de Galicia. Portadores de N.Meningitidis e incidencia de enfermidade meningocócica. Boletín Epidemiolóxico de Galicia 1997; Vol X, n.o 3.